Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for enrollment into this study, subjects must meet all of the following criteria:~* Completion of study OB-303 (NCT00553787) on treatment and compliance with all protocol requirements~* Written informed consent~* Female subjects of childbearing potential must be using adequate contraception, defined as double-barrier methods, stable hormonal contraception plus single barrier method, or tubal ligation. Female subjects are considered to be of childbearing potential unless they have undergone a hysterectomy or bilateral oophorectomy, are ≥55 years of age and experienced spontaneous cessation of menses for at least 1 year, or have a documented follicle-stimulating hormone level ≥40 IU/L~* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~Exclusion Criteria:~Subjects will not be included in the study if they meet any of the following:~* Body mass index ≤22 kg/m2 at the completion of study OB-303~* Off study medication at completion of study OB-303 (NCT00553787) for longer than 4 weeks continuously due to an event-driven holiday, or off study medication with no plans to restart~* Development of any condition during study OB-303 (NCT00553787) that, in the opinion of the investigator, would contraindicate the administration of study medication, affect compliance, interfere with study evaluations, or confound the interpretation of study results~* Participation in a formal weight loss program (including: Weight Watchers and related dietary/lifestyle intervention programs; prepared food programs; prescribed or over the counter weight loss medications; dietary supplement or herbal preparations, teas, or tinctures intended for weight loss; or any supervised fast or very low calorie diet).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- VI-0521 Mid (Type: EXPERIMENTAL): 7.5 mg phentermine and 46 mg topiramate
- VI-0521 Top (Type: EXPERIMENTAL): 15 mg phentermine and 92 mg topiramate

Based on this trial design, predict the completion outcome and termination type (if applicable).